Three patents currently held, every record listed here
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2026. from the record
Of the 4 now held by other companies, 4 name Biolitec Unternehmensbeteiligungs II AG as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Dec 2026
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2008 to 2042.
US 8,709,449
Methods and compositions for improving photodynamic therapy through administration of lipids
May 4, 2029
US 12,276,830
Preforms for Speckle-Free Output Optical Fibers Having Structured Silica Sections, Methods of Such Preform Manufacture, and Improved Speckle-Free Output Optical Fibers
Feb 25, 2041
US 12,364,759
Polymer-Particle Light-Cleavable Carrier Systems for Photodynamic Therapy
Jun 12, 2042
20152022202920362042
8 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Dec 2026 · High confidence
Also notable
Ends Feb 2041 · High confidence
Remote Monitoring Method with Event-Triggered Warning Capability
US 7,397,383
Renewed at every maintenance window since the 2008 grant; no more fees are due before its term ends in 2026.
Preforms for Speckle-Free Output Optical Fibers Having Structured Silica Sections, Methods of Such Preform Manufacture, and Improved Speckle-Free Output Optical Fibers
US 12,276,830
Granted 2025. Too new for citation comparison; protection runs to 2041.
Formerly held, still cited
Notable
Ends Mar 2030 · High confidence
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2030.
now held by Biolitec Unternehmensbeteiligungs II AG
Also notable
Ends Dec 2031 · High confidence
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2031.
now held by Biolitec Unternehmensbeteiligungs II AG
Also notable
Ends May 2029 · High confidence
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2029.
now held by Biolitec Unternehmensbeteiligungs II AG
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 3 terms have ended since Aug 16, 2026
What they patent
The 2 largest of its 3 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,397,383 | Remote Monitoring Method with Event-Triggered Warning Capability held by Biolitec Pharma Marketing Ltd. In force · High confidence | In force | High confidence | |
| US 12,276,830 | Preforms for Speckle-Free Output Optical Fibers Having Structured Silica Sections, Methods of Such Preform Manufacture, and Improved Speckle-Free Output Optical Fibers held by Biolitec Holding GmbH & Co. KG In force · High confidence | In force | High confidence | |
| US 12,364,759 | Polymer-Particle Light-Cleavable Carrier Systems for Photodynamic Therapy In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 4 patents in force now held by others · 41 patents ended · 8 applications pending · 32 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed